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MaBACKGROUND Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary heart disease
(CHD) events has conﬂicting results. We previously observed the haptoglobin (Hp) Hp2-2 genotype is associated with a
w10-fold increased CHD risk among individuals with HbA1c $6.5%, and thus might be useful in identifying those at high
risk of CHD who would beneﬁt from maintaining HbA1c <6.5%.
OBJECTIVES This study sought to model whether HbA1c $ 6.5% in the Hp2-2 genotype is associated with CHD in a
prospective case-control study nested within the Health Professionals Follow-Up Study (HPFS).
METHODS HbA1c concentration and Hp genotype were determined for 695 incident cases of CHD from 1994 to 2010 and
matched control participants. Logistic regression models calculated relative risk (RR) and 95% CI, for the ﬁrst and second
halves of follow-up, adjusting for confounding variables. A dataset from the Nurses’ Health Study served as a replication
cohort.
RESULTS The prevalence of the Hp2-2 genotype in HPFS was 39%. Compared with HbA1c <6.5%, the RR of CHD for
HbA1c $6.5% for the Hp2-2 genotype over full follow-up was 3.07 (95% CI: 1.37 to 6.86) to 3.88 (95% CI: 1.31 to 11.52)
during the ﬁrst half of follow-up and 2.16 (95% CI: 0.61 to 7.61) in the second half. The corresponding RRs for the
Hp1-1 þ Hp2-1 genotypes were: full follow-up, 2.19 (95% CI: 1.14 to 4.24); ﬁrst half, 1.60 (95% CI: 0.73 to 3.53);
and second half, 4.72 (95% CI: 1.26 to 17.65).
CONCLUSIONS In 2 independent cohorts, the risk of CHD associated with HbA1c $6.5% is pronounced in the Hp2-2
genotype, particularly in early cases. The Hp2-2 genotype may identify individuals at greatest CHD risk from
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ABBR EV I A T I ON S
AND ACRONYMS
CHD = coronary heart disease
CNV = copy number variant
GWAS = genome-wide
association study
HbA1c = hemoglobin A1c
HDL = high-density lipoprotein
Hp = haptoglobin
HPFS = Health Professionals
Follow-Up Study
MI = myocardial infarction
RR = relative risk
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1792L arge, randomized, controlled trialsthat have targeted glycosylated hemo-globin A1c (HbA1c) to a concentration
of <6.5% among participants with diabetes
mellitus have found signiﬁcant reduction in
cardiovascular outcomes in some (1,2) but
not all (3,4) studies. This inconsistency may
be due in part to different unknown charac-
teristics among patient subgroups, which
have not yet been explored (5). The common
haptoglobin (Hp) copy number variant (CNV)
(rs72294371) has 3 genotypes (Hp1-1, Hp2-1,
and Hp2-2) with frequencies that differ
among populations (6) and may explainpotentially the differences in the efﬁcacy of strict gly-
cemic control between study populations. The pri-
mary function of Hp is to protect against oxidative
damage from extracorpuscular hemoglobin (7). The 3
Hp genotypes produce structurally different Hp pro-
teins, of which the Hp2-2 is the least functional—
an impairment that is further accentuated when
hemoglobin is glycosylated (8). Currently available
genome-wide association study (GWAS) technologies
have not been found to capture the Hp CNV polymor-
phism, explaining why the association of this poly-
morphism with cardiovascular disease in the setting
of elevated blood glucose has not been investigated
in cohorts screened only by GWAS (9–11).SEE PAGE 1800In 2 independent populations, we have observed
that participants with both the Hp2-2 genotype (ho-
mozygous for presence of CNV) and HbA1c $6.5% had
a 10-fold higher risk of coronary heart disease (CHD)
compared with those with at least 1 Hp1 allele and
HbA1c <6.5% (12). However, a recent analysis of car-
diovascular disease among adults in the Bruneck
study did not observe a similar association (13). The
discrepancy may be due to several study design fac-
tors, especially the combined endpoint of CHD and
stroke (the majority of cases were stroke), because
stroke has been associated with the Hp1-1 genotype
rather than the Hp2-2 genotype (14,15). However, the
Bruneck study is of interest because it contained
repeated measures of HbA1c and provides suggestive
evidence for a potential time-dependent bias against
the Hp2-2 genotype as participants aged that supports
previous ﬁndings of increased longevity among in-
dividuals with the Hp1-1 genotype (16,17). Thus, if
Hp2-2 individuals are at increased risk of early dis-
ease and death, it strengthens the growing evidence
behind the hypothesis that targeted screening and
treatment for the Hp2-2 genotype in cases of HbA1c
$6.5% could prevent coronary events.In the present study, we used a large prospective
case-control study nested within a cohort of healthy
men at baseline to further examine the interaction
between the Hp polymorphism and HbA1c concen-
tration on risk of CHD, testing the hypothesis that
targeted screening for the Hp2-2 genotype in the
setting of HbA1c $6.5% may be prudent. Because
previous long-term studies have reported that the
association between HbA1c and the risk of CHD
is strongest in the earliest years of follow-up (18),
we examined the ﬁrst and second halves of follow-up
separately as well as together. We then sought repli-
cation of our full analysis in a complementary, but
independent, cohort of women.
METHODS
COHORT: THE HEALTH PROFESSIONALS FOLLOW-UP
STUDY. The Health Professionals Follow-up Study
(HPFS) is a prospective cohort of 51,529 male health
professionals whowere 40 to 75 years of age at baseline
in 1986. Information on anthropometric and lifestyle
factors is obtained through self-administered ques-
tionnaires every 2 years and diet every 4 years. Blood
sampleswere collected fromparticipants free of cancer
and without prior cardiovascular events in 1993 to
1995. Men who had an incident myocardial infarction
(MI) or fatal CHD between the date of blood draw and
January 2010 were identiﬁed and matched 1:1 with
control participants with the same age, smoking sta-
tus, and month of blood draw. Participants were
excluded from the ﬁnal sample in the present analysis
if they were missing data on the exposures or the
outcome. Using 2-tailed tests, the type I error proba-
bility of 0.05, a prevalence in control participants of
0.39 for the Hp2-2 genotype, and ourﬁnal HPFS sample
size of 695 casesmatched 1:1 to control participants, we
have >90% power to detect an odds ratio of 1.50. The
majority of participants (>95%) in this case-control
sample are Caucasian. Anthropometric and lifestyle
variables were derived from the questionnaire
administered in 1994, with missing information
substituted from the 2 previous questionnaires. The
validity of the questionnaires and the reproducibility
of the measurements have been previously reported
(19). The Institutional Review Board of the Brigham
and Women’s Hospital and the Human Subjects Com-
mittee Review Board of Harvard T. H. Chan School of
Public Health approved the study protocol.
REPLICATION COHORT: THE NURSES’ HEALTH
STUDY. The Nurses’ Health Study (NHS) is a prospec-
tive cohort of 121,700 female US registered nurses who
were 30 to 55 years of age at baseline in 1976. Infor-
mation on anthropometric and lifestyle factors is
J A C C V O L . 6 6 , N O . 1 6 , 2 0 1 5 Cahill et al.
O C T O B E R 2 0 , 2 0 1 5 : 1 7 9 1 – 9 HbA1c, Hp2-2 Genotype, and Coronary Disease
1793obtained through self-administered questionnaires
every 2 years and diet every 4 years. From 1989 to
1990, a blood sample was provided by 32,826 women.
Women who had an incident MI or fatal CHD between
the date of blood draw and June 2004 were identiﬁed
and matched 1:1 with control participants for age,
smoking status, fasting status, and month of blood
draw, as described elsewhere (20). Details of the ge-
notype frequencies and baseline characteristics of the
speciﬁc sample used in this present study have been
previously reported (12), but the hypothesis tested is
new in the present study. Using 2-tailed tests, the type
I error probability of 0.05, a prevalence in control
participants of 0.39 for the Hp2-2 genotype, and our
ﬁnal NHS sample size of 400 cases matched 1:1 to
control participants, we have>80% power to detect an
odds ratio of 1.50.
Hp TYPING. Although recently given the identiﬁer
rs72294371 (21), the Hp polymorphism is not a single
nucleotide polymorphism; it is a CNV deﬁned by the
absence (Hp1 allele) or presence (Hp2 allele) of a 1.7 kb
partial in-frame intragenic duplication of exons 3 and
4. Hp type was determined in both cohorts by protein
gel electrophoresis of hemoglobin-enriched serum
(22). This procedure produces a ﬁngerprint banding
pattern for each Hp type and has been shown to
correspond completely with the Hp genotype (23).
Currently available GWAS platforms do not include the
HpCNVpolymorphism (9–11). Genotype frequencies in
the HPFS were in Hardy-Weinberg equilibrium in the
whole sample (p ¼ 0.08) and also within cases (p ¼
0.28) and control participants (p ¼ 0.17) separately.
Genotype frequencies in the NHS were also in Hardy–
Weinberg equilibrium, as reported previously (12).
CHD CASE ASSESSMENT. As previously detailed in
the HPFS (24) and the NHS (25), CHD is similarly
deﬁned in the 2 datasets as nonfatal MI or fatal CHD,
but does not include the development of coronary
atherosclerosis which has not resulted in an acute
coronary syndrome. MI was diagnosed on the basis of
the criteria of the World Health Organization (symp-
toms plus either diagnostic electrocardiographic
changes or altered levels of cardiac enzymes) (26).
After a participant reported a nonfatal event on a
questionnaire, the case was conﬁrmed through the
review of medical records by physicians blinded to
the self-report. Deaths were identiﬁed from state vital
records and the National Death Index or reported by
the participant’s next of kin or the postal system.
Fatal CHD was conﬁrmed by an examination of hos-
pital or autopsy records.
STATISTICAL ANALYSIS. Participant characteristics
were compared between cases and controlparticipants using Student t tests for continuous var-
iables and chi-square tests for categorical variables.
For skewed variables (physical activity, alcohol, high
sensitivity C-reactive protein, high-density lipopro-
tein [HDL] cholesterol, HbA1c, and triglycerides), p
values from log-transformed analyses andmedian and
interquartile ranges were determined. The primary
hypothesis we tested was that HbA1c $6.5% in the risk
genotype (Hp2-2) is associated with CHD in a pro-
spective nested case-control study. Because of the
nested case-control study design, relative risks (RRs)
of CHD were estimated by incidence rate ratios from
logistic regression with adjustment for the matching
factors. In addition to matching factors, analyses were
adjusted for body mass index, alcohol, physical ac-
tivity, parental MI before the age of 60, diet quality
score (the 2010 Alternate Healthy Eating Index) (27),
history of high cholesterol, history of high blood
pressure, and medications for high blood pressure. We
used an a priori cutpoint of 6.5% for HbA1c, because
this is the level for complications from hyperglycemia
as established by the International Expert Committee
composed of members of the American Diabetes As-
sociation, the European Association for the Study of
Diabetes, and the International Diabetes Federation
(28). Because of the low frequency of the Hp1-1 ge-
notype (w15%) and the structure (29) and function (30)
of the different Hp proteins, we used a common
approach of combining the Hp1-1 and Hp 2-1 genotype
for most analyses (13). Because a single measure of
HbA1c at baseline has been shown to be differently
associated with short-term CHD risk than long-term
CHD risk (18), we conducted analyses within halves of
follow-up (ﬁrst 8 years and second 8 years), in addition
to examining the full follow-up period. To pool the risk
estimates from multiple study cohorts, we used the
weighted average of regression estimates in a random-
effects meta-analysis, and tested for between-study
heterogeneity (31). All analyses were conducted using
SAS software version 9.3 (SAS Institute, Cary, North
Carolina), at a 2-tailed alpha level of 0.05.
RESULTS
The distribution of Hp genotype frequencies in the
HPFS cohort was 16% (Hp1-1), 45% (Hp2-1), and 39%
(Hp2-2). The Hp genotype frequency did not differ
between cases and control participants. Baseline
characteristics by case-control status are described in
Table 1. As expected, cases drank less alcohol and had
a lower diet quality than control participants, and had
higher body mass index, family history of CHD prev-
alence of hypertension, diabetes, hypercholesterole-
mia, and greater medication use at baseline.
TABLE 1 Baseline Characteristics by Case Status Among Men 46 to 80 Years of Age at
Blood Draw From the Nested Case-Control Study of Coronary Heart Disease Events in the
Health Professionals Follow-Up Study (1994 to 2010)
Cases
(n ¼ 695)
Control Participants
(n ¼ 696) p Value
Age, yrs* 63.1  8.7 63.0  8.7 —
Age at event/matched event, yrs 70.0  8.2 70.0  8.2 —
Time to event, yrs 6.9  4.4 6.9  4.4 —
Smoking status*
Never 317 (46) 318(46) —
Past 327 (47) 336 (48) —
Current 51 (7) 42 (6) —
Married 614 (88) 620 (89) 0.66
BMI, kg/m2 26.3  3.3 25.7  3.5 0.001
Activity, MET h/week 24.2 (9.5-47.5) 25.6 (11.2-49.8) 0.19
Alcohol, g/d 4.4 (0.0-14.0) 7.0 (1.0-17.6) <0.0001
AHEI 2010 Diet Quality Score 53.2  11.5 54.5  11.4 0.03
Parental MI <60 years of age 281 (40) 234 (34) 0.009
History of hypercholesterolemia 346 (50) 259 (37) <0.0001
History of hypertension 261 (38) 184 (26) <0.0001
History of diabetes 57 (8) 19 (3) <0.0001
Diabetes† 117 (17) 40 (6) <0.0001
Aspirin $5 days/week 179 (26) 150 (22) 0.07
Cholesterol-lowering drug use 55 (8) 45 (6) 0.29
Antihypertensive drug use 188 (27) 135 (19) 0.0007
Diabetes medication† 75 (11) 32 (5) <0.0001
CRP, mg/l 1.40 (0.65-2.72) 0.93 (0.47-1.87) <0.0001
Triglycerides, mg/dl 138 (93-195) 114 (83-164) <0.0001
HbA1c, % 5.70 (5.44-5.96) 5.62 (5.36-5.84) <0.0001
HbA1c $6.5% 65 (9) 23 (3) <0.0001
Total cholesterol, mg/dl 206  37 200  33 0.0006
HDL cholesterol, mg/dl 41 (35-48) 45 (38-54) <0.0001
LDL cholesterol, mg/dl 135  34 129  31 0.0005
Apolipoprotein B, mg/dl‡ 98  24 90  20 <0.0001
Haptoglobin genotype
1-1 112 (16) 109 (695) 0.78
2-1 317 (46) 312 (45)
2-2 266 (38) 275 (39)
Values are mean  SD, n (%), or median (interquartile range). Participant characteristics were compared between
genotypes using a Student t-test for continuous variables and chi-square tests for categorical variables. For
skewed variables (physical activity, alcohol, CRP, HDL, HbA1c and triglycerides), p values from log-transformed
analyses and median and interquartile ranges are reported. *Age and smoking status were matching factors,
and thus no differences were observed. †Cases were updated as having diabetes if they developed diabetes
before their CHD event (control participants if diagnosed with diabetes before their matched case had a CHD
event). Diabetes medication use includes medications initiated during follow-up. ‡n ¼ 424 cases and 421 control
participants for apolipoprotein B.
AHEI ¼ alternate healthy eating index; BMI ¼ body mass index; CRP ¼ high sensitivity C-reactive protein;
HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; MET ¼
metabolic equivalent; MI ¼ myocardial infarction.
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separately, Table 2 presents the multivariate-adjusted
RR and 95% CI of CHD when HbA1c was $6.5%
compared with when HbA1c <6.5%. HPFS participants
with the Hp2-2 genotype had a multivariate RR of 3.07
(95% CI: 1.37 to 6.86) if their HbA1c was $6.5%
compared with if it was <6.5%, and the corresponding
RR for the Hp1-1 þ Hp2-1 genotypes (Hp 1 allele car-
riers) was 2.19 (95% CI: 1.14 to 4.24). Although withlimited power, when earlier and later CHD events
were examined separately, the risk of CHD associated
with HbA1c $6.5% for the Hp2-2 genotype was greater
in the earlier HPFS cases (RR: 3.88, 95% CI: 1.31 to
11.52 for events that occurred in the ﬁrst 8 years) and
less so in the later cases (RR: 2.16; 95% CI: 0.61 to 7.61
for events that occurred in the last 8 years). The
reverse pattern was observed for the HPFS partici-
pants with the Hp1-1þHp2-1 genotypes.
We have reported previously preliminary results
from the NHS, which found an increased risk of CHD
among participants with both HbA1c $6.5% and the
Hp2-2 genotype (12). When we reanalyzed the NHS
with identical methods to our present HPFS analysis
and pooled results, our ﬁndings were strong and
consistent. The risk of CHD associated with HbA1c
$6.5% for the Hp2-2 genotype was substantial (RR:
10.59; 95% CI: 2.34 to 47.91), but even potentially
greater when we restricted the analysis to the ﬁrst
8 years after blood draw (RR: 28.62; 95% CI: 3.27 to
250.72), and was not signiﬁcant after the ﬁrst 8 years of
follow-up (RR: 4.98; 95% CI: 0.54 to 46.16) (Table 2).
Among NHS participants, the RR of CHD for
HbA1c $6.5% was not signiﬁcant for the Hp1-1þHp2-1
genotypes (RR: 2.12; 95% CI: 0.98 to 4.60). Pooling
the results from the HPFS and NHS substantially
increased the power and highlighted the differences in
the RR of CHD for HbA1c $6.5% among the Hp 2-2 ge-
notypes (RR: 8.38; 95% CI: 1.25 to 56.32) and Hp1 car-
riers (RR: 2.12; 95% CI: 1.02 to 4.39) during the ﬁrst 8
years of follow-up. The multivariate-adjusted p values
for the tests of interaction were not signiﬁcant. Results
were not appreciably altered by further adjustment for
cholesterol-lowering medications, such as statins,
including those taken during the follow-up period.
In keeping with the format of previous analyses
(12), pooled risk of CHD was calculated for HPFS and
NHS participants together, with participants grouped
by the combination of their Hp genotype and HbA1c
status (Online Figure 1). Compared with participants
who carried an Hp1 allele and had HbA1c <6.5%,
those with the Hp2-2 genotype and HbA1c $6.5% had
a 4.25-fold increased risk of CHD (95% CI: 1.05 to
17.22), whereas those with the Hp2-2 genotype and
HbA1c <6.5% did not have a signiﬁcant risk of CHD
(RR: 0.92; 95% CI: 0.69 to 1.23).
DISCUSSION
In a prospective, nested, case-control study design
with 16 years of follow-up, HbA1c $6.5% was a strong
and signiﬁcant predictor of CHD among men with
the Hp2-2 genotype, especially in the cases most
proximal to blood draw. Our results are strengthened
TABLE 2 Adjusted RR of CHD With 95% CI for HbA1c $6.5% Stratiﬁed by Hp Genotypes in Men 46 to 80 Years of Age at Blood Draw From
the Nested Case-Control Study of CHD Events in the HPFS (1994 to 2010) and in Women 44 to 69 Years of Age at Blood Draw From the
Nested Case-Control Study of CHD Events in the NHS (1990 to 2004)
Haptoglobin Genotype
p Value,
Interaction
Hp1-1 þ Hp2-1 Hp2-2
HbA1c
<6.5%
HbA1c
$6.5%
HbA1c
<6.5%
HbA1c
$6.5%
HPFS
All participants together
N, cases/control participants 393/407 36/14 237/266 29/9
RR (95% CI) 1.00 (Ref.) 2.19 (1.14-4.24) 1.00 (Ref.) 3.07 (1.37-6.86) 0.76
First half (8 yrs) of follow-up
N, cases/control participants 231/235 21/11 135/150 19/5
RR (95% CI) 1.00 (Ref.) 1.60 (0.73-3.53) 1.00 (Ref.) 3.88 (1.31-11.52) 0.41
Second half of follow-up
N, cases/control participants 162/172 15/3 102/116 10/4
RR (95% CI) 1.00 (Ref.) 4.72 (1.26-17.65) 1.00 (Ref.) 2.16 (0.61-7.61) 0.42
NHS
All participants together
N, cases/control participants 212/239 33/11 135/148 24/2
RR (95% CI) 1.00 (Ref.) 2.12 (0.98-4.60) 1.00 (Ref.) 10.59 (2.34-47.91) 0.05
First 8 yrs of follow-up
N, cases/control participants 104/108 25/5 47/77 17/1
RR (95% CI) 1.00 (Ref.) 3.46 (1.14-10.55) 1.00 (Ref.) 28.62 (3.27-250.72) 0.09
After ﬁrst 8 yrs of follow-up
N, cases/control participants 108/131 8/6 88/71 7/1
RR (95% CI) 1.00 (Ref.) 0.92 (0.27-3.07) 1.00 (Ref.) 4.98 (0.54-46.16) 0.17
NHS and HPFS pooled
All participants
N, cases/control participants 605/646 69/25 372/418 53/11
RR (95% CI) 1.00 (Ref.) 2.16 (1.31-3.57) 1.00 (Ref.) 4.80 (1.49-15.42) 0.30
First 8 yrs of follow-up
N, cases/control participants 335/343 46/16 182/231 36/6
RR (95% CI) 1.00 (Ref.) 2.12 (1.02-4.39) 1.00 (Ref.) 8.38 (1.25-56.32) 0.15
After 8 years of follow-up
N, cases/control participants 270/303 23/9 190/187 17/5
RR (95% CI) 1.00 (Ref.) 2.03 (0.41-10.13) 1.00 (Ref.) 2.64 (0.88-7.92) 0.78
The multivariate model is adjusted for matching factors (age and smoking) and also: body mass index, alcohol, physical activity, parental coronary heart disease before the age
of 60 years, diet quality score, history of high cholesterol, history of high blood pressure, and medications for high blood pressure.
HPFS ¼ Health Professionals Follow-Up Study; NHS ¼ Nurses Health Study; Ref. ¼ reference group; RR ¼ relative risk; other abbreviations as in Table 1.
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data from a second cohort.
In 2 independent cohorts with a broad range
of HbA1c concentrations (the Israel Cardiovascular
Events Reduction With Vitamin E Study, and the same
NHS dataset used as a replication cohort in the present
study), we have reported previously that individuals
with the Hp2-2 genotype and HbA1c $6.5% had a >10-
fold increased risk of CHD compared with those with
anHp1 allele andHbA1c<6.5% (12). Previously reported
results from the Strong Heart Study data support
additional replication (12,32). However, a recent lon-
gitudinal analysis of cardiovascular disease among
adults in the Bruneck study did not report that HbA1c
$6.5% in the Hp2-2 genotype was predictive ofcardiovascular disease (13). The authors did not pre-
sent directly the RR of CHD for HbA1c$6.5% among the
Hp2-2 subgroup, but did present a nonsigniﬁcant risk
(multivariate-adjusted RR: 0.35; 95% CI: 0.08 to 1.52)
for the Hp2-2 versus Hp2-1þHp1-1 genotypes in the
strata of participants with HbA1c $6.5%. The discrep-
ancy in ﬁndings may be due to several distinguishing
factors. For example, the Bruneck study included
participantswith prevalent disease at baseline and had
a small number of cases during the 15 years of follow-
up (123 cases, among which only 48 cases were CHD).
The endpoint of CHD was combined with stroke, an
endpoint that has been associated with the Hp1-1 ge-
notype rather than Hp2-2 (14,15). It has been suggested
that the protection conferred by the Hp1-1 genotype
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Hp as the scavenger of free hemoglobin, whereas the
role of Hp in angiogenesis may confer the protection
against stroke associated with the Hp2-2 phenotype
(33,34).
A single biomarker at baseline may be a better
proxy for exposure over the ﬁrst several years, and
possibly become less correlated with exposure over a
longer period of time. In a recent 14-year study of
HbA1c and risk of CHD, when we stratiﬁed according
to the midpoint of follow-up, the association was
strongest among cases and control participants in the
ﬁrst half (ﬁrst 7 years) of follow-up, even when
limited to only participants with HbA1c <6.5% (18). In
the present analysis, when we analyzed the HPFS
data in halves of follow-up (two 8-year-long studies
instead of one 16-year-long study), we observed an
increased risk of CHD in the Hp2-2 participants with
HbA1c $6.5% in the ﬁrst half, but not the second half
of follow-up, and an increased risk of CHD in the Hp1-
1þ Hp2-1 participants with HbA1c $6.5% in the second
half of follow-up but not the ﬁrst half. We observed
the same pattern in the NHS data as well. It is possible
that our single measurement of HbA1c may not be a
strong predictor of risk beyond 8 years. In our pilot
studies, HbA1c did have a strong intraclass correlation
of 0.73 over a 3-year period (r between draws ¼ 0.88;
n ¼ 83), but when HbA1c was measured in blood
samples collected 10 years apart, the intraclass cor-
relation was 0.45 (r between draws ¼ 0.68; n ¼ 244),
which suggests good within-person reproducibility of
HbA1c over periods of time as long as a decade, but
that this reproducibility still decays over time. The
fact that the correlations between draws are higher
than the intraclass correlations indicates that the
HbA1c is changing in the same direction for partici-
pants. Indeed, HbA1c levels are associated positively
with age, even among populations without impaired
fasting glucose (35,36), suggesting that HbA1c $6.5%
may be a weaker marker of risk among older pop-
ulations. However, the increase in HbA1c with age is
considered to be modest (37) and age-speciﬁc diag-
nostic and treatment criteria do not exist.
If individuals with the Hp2-2 genotype are more
susceptible to CHD, they may have cardiovascular
events at an earlier age and have overall reduced
longevity than the other genotypes, creating a survi-
vor bias or depletion of susceptibles that may explain
in part why we observe a stronger association in the
earlier follow-up years and even a reverse pattern in
the later years. Analyses in Bruneck participants
stratiﬁed by age displayed an interesting pattern: in
participants age 75 years or older only, the risk of
cardiovascular disease for the Hp2-2 type comparedwith the Hp1-1 type was 0.11 (95% CI: 0.01 to 0.95)
among those with HbA1c $6.5%, suggesting a poten-
tial survivor bias against the Hp2-2 genotype with
increased age. This is consistent with previous
studies that suggest increased longevity among in-
dividuals with the Hp1-1 genotype (16,17).
BIOLOGICAL MECHANISMS. The large difference in
size of the Hp CNV’s 2 alleles, Hp1 and Hp2, results in
structurally and functionally different proteins being
formed by each of the 3 genotypes (38). Hb released
intravascularly from erythrocytes is rapidly bound by
Hp protein to form an Hp–Hb complex that is cleared
by the monocyte/macrophage scavenger receptor
CD163. However, this clearance by CD163 is impaired
in Hp2-2 individuals as well as under hypergly-
cemic conditions, resulting in increased amounts of
circulating Hp2-2:Hb complex in Hp2-2 individuals
with hyperglycemia (8,39) (Central Illustration).
Further, the glycosylation of hemoglobin impairs the
ability of the Hp2-2 protein to act as an antioxidant,
thus resulting in increased oxidative activity of the
glycosylated Hp2:Hb complex (8). This pro-oxidant
Hp2-2:Hb complex can bind to HDL and produce
reactive oxygen species that oxidize HDL and its
related components, such as apolipoprotein A,
glutathione peroxidase, and lecithin-cholesterol
acyltransferase, thereby decreasing the function of
HDL as both an antioxidant and in its role in reverse
cholesterol transport, and paradoxically turning the
HDL into a proatherogenic prothrombotic molecule
(8,39–43). Our results were stronger in our analysis of
women than of men, potentially due to higher HDL
among women and thus more inﬂuence from the
dysfunctional HDL associated with the Hp2-2 geno-
type in the setting of hyperglycemia. However, we
were unable to assess this potential sex difference
directly in the present study.
IMPLICATIONS. Replication is required to conﬁrm
ﬁndings from the present study, and should be
attempted in a randomized trial targeting HbA1c to
concentrations <6.5%, such as the ACCORD (Action
to Control Cardiovascular Risk in Diabetes) study (4),
the ADVANCE (Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron Modiﬁed Release
Controlled Evaluation) trial (1), and the VADT (Vet-
erans Affairs Diabetes Trial) (3). These studies have
reported conﬂicting results regarding the efﬁcacy of
achievement of HbA1c concentrations of <6.5% to
prevent cardiovascular disease, an inconsistency that
may be due in part to different unknown character-
istics among patient subgroups, which have not yet
been explored, as recently suggested in a meta-
analysis (5). Unfortunately, currently available ver-
sions of single nucleotide polymorphism chips and
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1797tagging single nucleotide polymorphisms cannot be
used to query the common Hp polymorphism (9), so
replication or conﬁrmation of our ﬁndings by GWAS is
not possible. However, several genotyping and phe-
notyping methods exist that easily allow for direct
assessment of the Hp CNV polymorphism and could
be used to determine Hp genotype in ACCORD,
ADVANCE, or VADT. Such an investigation, with afollow-up length of 3 to 5 years, could further
decrease the risk of survival bias for the Hp2-2 ge-
notype subgroup, and could also reﬂect a more con-
temporary sample than our own, due to medication
use and biomarker concentrations that better reﬂect
current clinical settings. If our ﬁndings are replicated,
Hp genotyping could potentially assist in identifying
the genetically susceptible individuals who would
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Pre-
vious randomized trials of interventions targeting
strict glycemic control (hemoglobin A1c levels <6.5%)
to decrease cardiovascular events have yielded
inconsistent results.
TRANSLATIONAL OUTLOOK: Further studies are
needed to determine whether aggressive glycemic
control is more effective in preventing cardiovascular
events when applied to individuals with speciﬁc Hp
genotypes.
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1798most beneﬁt from targeted clinical management of
HbA1c.
STUDY STRENGTHS AND LIMITATIONS. Strengths of
the present analysis include comprehensive data
gathered prospectively with a long duration of follow-
up, replication in a second cohort, and a validated Hp
genotypingmethod. Themain limitation of the present
study is that we only had a single measurement of
HbA1c, taken at baseline, which became less proximal
during each year of follow-up. Thus, random error
caused by normal ﬂuctuations and increases in HbA1c
with age (35,36) could cause underestimation of true
RRs, or the biomarker may lose effectiveness as a
measure of glycemia over time. Although we had a
large number of cases and our results were signiﬁcant,
we lost power due to multiple stratiﬁcations, and the
conﬁdence intervals that we observed are wide, thus
the exact risk estimate is difﬁcult to estimate with
much precision, and our main hypothesis needs
conﬁrmation within an intervention study design.
Tests of interaction were underpowered, especially
when adjusted for covariates. Bias from residual con-
founding is a potential limitation; however, our cases
and control participants were matched on age and
smoking (the 2 strongest CHD risk factors), and our
multivariate model showed little attenuation by
known CHD risk factors. Another important limitation
is that the participants we studied are predominantly
Caucasian, so it is unknown whether the associations
we observed would be similar in non-Caucasian
populations.
CONCLUSIONS
In 2 independent cohorts, the risk of CHD associated
with HbA1c $6.5% was intensiﬁed in individuals with
the Hp2-2 genotype, an association that was pro-
nounced in the earlier half of cases in this prospective
nested case-control study. If replicated, the resultsof the present study suggest that targeted screening
for the Hp polymorphism among individuals with
HbA1c $6.5% could help to identify the patients who
would most beneﬁt from interventions to lower gly-
cemia to HbA1c concentrations of <6.5%. The present
study also suggests that aging and time-dependent
bias limit observational research of the Hp poly-
morphism, and thus results would best be conﬁrmed
within a randomized clinical trial study design.
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